[ad_1]
The US Food and Drug Administration (FDA) has adopted the first combination of chemotherapy for breast cancer, particularly after successfully treating a number of cancers such as lung cancer, skin cancer and bladder cancer.
According to the Swiss company Roche, the new treatment, which adds to the usual drugs, includes the drug "Atizolizumab" for immunotherapy and the drug "Napacletix" which is an effective way of treating women in whom a triple breast cancer was diagnosed.
Dr. Jim Abraham, an oncologist at Cleveland Clinic, one of the leading cancer treatment hospitals, said, "This type of treatment is for some patients with advanced breast cancer, in which the disease is transmitted from the breast to other parts of the body, for the treatment of triple negative breast cancer.
Meanwhile, Dr. Amy Tersten, a cancer specialist, said that according to her study, which involved 600 women with triple negative breast cancer, the results of those receiving the new treatment were acceptable, their disease was not diagnosed. Not aggravating compared to those receiving chemotherapy alone.
[ad_2]
Source link
